Issue 145 | August 2024
Left in limbo: when pharma halts rare disease research
In this issue: Saving abandoned gene therapy programs, exploring the genAI boom in pharma, the evolution of South Korea’s reimbursement administration, understanding the FDA’s latest clinical trial diversity guidance, and more.